Pharmacological effects of PARP inhibitors on cancer and other diseases

Current Enzyme Inhibition

Volumn 7, Issue 4, 2011, Pages 244-258

  Guamán Ortiz, Luis M ^a,b   Giansanti, Vincenzo ^a   Donà, Francesca ^a   Ivana Scovassi, A ^a  

^a CNR   (Italy)

^b UNIVERSIDAD TÉCNICA PARTICULAR DE LOJA   (Ecuador)

Author keywords

Cancer; Cell death; DNA repair; Inflammation; Neurodegenerative diseases; PARG inhibitors; PARP inhibitors; Poly(ADP ribosylation); Tankyrases

Indexed keywords

1,5 DIHYDROXYISO QUINOLINE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; 3 AMINOBENZAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; BENZAMIDE; BENZIMIDAZOLE; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAPORINAD; DR 2313; GPI 15427; INIPARIB; INO 1001; IRINOTECAN; MP 124; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PEPLEOMYCIN; PHLOXINE; RHODANINE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BRAIN DEATH; BRAIN ISCHEMIA; CANCER INHIBITION; CELL DEATH; CELL PROTECTION; CHEMICAL STRUCTURE; CHEMOSENSITIZATION; CYTOTOXICITY; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DNA TRANSCRIPTION; EHRLICH ASCITES TUMOR; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE DELETION; HEART DISEASE; HEART FAILURE; HEAT STROKE; HUMAN; INFLAMMATION; NEOPLASM; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN PROCESSING;

EID: 84858779583     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/157340811799860524     Document Type: Article

References (213)

1. Asher, G.; Reinke, H.; Altmeyer, M.; Gutierrez-Arcelus, M.; Hottiger, M.O.; Schibler, U. Poly(ADP-Ribose) Polymerase 1 participates in the phase entrainment of circadian clocks to feeding. Cell, 2010, 142, 943-953.
2. Citarelli, M.; Teotia, S.; Lamb, R.S. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol., 2010, 10, 1-26.
3. Ji, Y.; Tulin, A.V. The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Devel., 2010, 20, 512-518.
4. Schreiber, V.; Dantzer, F.; Amé, J.C.; de Murcia, G. Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7, 517-528.
5. Hassa, P.O.; Haenni, S.S.; Elser, M.; Hottiger, M.O. Nuclear ADPribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol. Mol. Biol. Rev., 2006, 70, 789-829.
6. Amé, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. BioEssays, 2004, 26, 882-893.
7. Hottiger, M.O.; Hassa, P.O.; Lüscher, B.; Schüler, H.; Koch-Nolte F. Toward a unified nomenclature for mammalian ADPribosyltransferases. Trends Biochem. Sci., 2010, 35, 208-219.
8. Hassa, P.O.; Hottiger, M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADPribose polymerases. Front. Biosci., 2008, 13, 3046-3082.
9. Frouin, I.; Scovassi, A.I. Poly(ADP-ribosylation) regulates DNA replication and repair. In DNA replication, repair and recombination at the crossroad between genome integrity and genomic instability: a biochemical perspective. Maga, G., Hübscher, U., Villani, G. Eds; Research Signpost, Kerala, India, 2008, pp. 116-130.
10. Hakme, A.; Wong, H.K.; Dantzer, F.; Schreiber, V. The expanding field of poly(ADP-ribosyl)ation reactions. EMBO Rep., 2008, 9, 1094-1100.
11. Caiafa, P.; Guastafierro, T.; Zampieri, M. Epigenetics: poly(ADPribosyl) ation of PARP-1 regulates genomic methylation patterns. FASEB J., 2009, 23, 672-678.
12. Quénet, D.; El Ramy, R.; Schreiber, V.; Dantzer, F. The role of poly(ADP-ribosyl)ation in epigenetic events. Int. J. Biochem. Cell Biol., 2009, 41, 60-65.
13. Kirkland, J.B. Poly ADP-ribose polymerase-1 and health. Exp. Biol. Med., 2010, 235, 561-568.
14. Krishnakumar, R.; Kraus, W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell., 2010, 39, 8-24.
15. Bürkle, A. DNA repair and PARP in aging. Free Radic. Res., 2006, 40, 1295-1302.
16. Jeggo, P.A. DNA repair: PARP - another guardian angel? Curr. Biol., 1998, 8, R 49-51.
17. Tong, W.M.; Cortes, U.; Wang, Z.Q. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim. Biophys. Acta, 2001, 1552, 27-37.
18. Woodhouse, B.C.; Dianov, G.L. Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair, 2008, 7, 1077-1086.
19. Till, S.; Diamantara, K.; Ladurner, A.G. PARP: a transferase by any other name. Nat. Struct. Mol. Biol., 2008, 15, 1243-1244.
20. Yélamos, J.; Schreiber, V.; Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med., 2008, 14, 169-178.
21. Cohausz, O.; Althaus, F.R. Role of PARP-1 and PARP-2 in the expression of apoptosis-regulating genes in HeLa cells. Cell Biol. Toxicol., 2009, 25, 379-91.
22. Karlberg, T.; Hammarström, M.; Schütz, P.; Svensson, L.; Schüler, H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry, 2010, 49, 1056-1058.
23. Quénet, D.; Mark, M.; Govin, J.; van Dorsselear, A.; Schreiber, V.; Khochbin, S.; Dantzer, F. Parp2 is required for the differentiation of post-meiotic germ cells: identification of a spermatid-specific complex containing Parp1, Parp2, TP2 and HSPA2. Exp. Cell Res., 2009, 315, 2824-2834.
24. Meyer-Ficca, M.L.; Lonchar, J.D.; Ihara, M.; Meistrich, M.L.; Austin, C.A.; Meyer, R.G. Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis. Biol. Reprod., 2011, 84, 900-909.
25. Rouleau, M.; McDonald, D.; Gagné, P.; Ouellet, M.E.; Droit, A.; Hunter, J.M.; Dutertre, S.; Prigent, C.; Hendzel, M.J.; Poirier, G.G. PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. J. Cell. Biochem., 2007, 100, 385-401.
26. Boehler, C.; Gauthier, L.R.; Mortusewicz, O.; Biard, D.S.; Saliou, J.M.; Bresson, A.; Sanglier-Cianferani, S.; Smith, S.; Schreiber, V.; Boussin, F.; Dantzer, F. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl. Acad. Sci. USA, 2011, 108, 2783-2788.
27. Rulten, S.; Fisher, A.; Robert, I.; Zuma, M.C.; Rouleau, R.; Ju, L.; Poirier, G.; Reina-San-Martin, B.; Caldecott, K.W. PARP-3 and APLF function together to accelerate non-homologous end-joining. Mol. Cell, 2011, 41, 33-45.
28. Augustin, A.; Spenlehauer, C.; Dumond, H.; Ménissier-De Murcia, J.; Piel, M.; Schmit, A.C.; Apiou, F.; Vonesch, J.L.; Kock, M.; Bornens, M.; de Murcia, G. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J. Cell Sci., 2003, 116, 1551-1562.
29. Rouleau, M.; Saxena, V.; Rodrigue, A.; Paquet, E.R.; Gagnon, A.; Hendzel, M.J.; Masson, J.Y.; Ekker, M.; Poirier, G.G. A key role for poly(ADP-ribose) polymerase 3 in ectodermal specification and neural crest development. PLoS One, 2011, 6, e15834.
30. Berger, W.; Steiner, E.; Grusch, M.; Elbling, L.; Micksche, M. Vaults and the major vault protein: Novel roles in signal pathway regulation and immunity. Cell. Mol. Life Sci., 2008, 66, 43-61
31. van Zon, A.; Mossink, M.H.; Schoester, M.; Houtsmuller, A.B.; Scheffer, G.L.; Scheper, R.J.; Sonneveld P.; Wiemer, E.A. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP. J. Cell Sci. 2003, 116, 4391-4400.
32. Liu, Y.; Snow, B.E.; Kickhoefer, V.A.; Erdmann, N.; Zhou, W.; Wakeham, A.; Gomez, M.; Rome, L.H.; Harrington, L. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. Mol. Cell Biol., 2004, 24, 5314-5323.
33. Bottone, M.G.; Santin, G.; Soldani, C.; Veneroni, P.; Alpini, C.; Scovassi, A.I.; Intracellular distribution of Tankyrases as detected by multicolor immunofluorescence techniques. Eur. J. Histochem., 2012, 56, e4.
34. Donà, F.; Mondello, C.; Scovassi, A.I. Poly(ADP-ribosylation) at telomeres. Trends Cell Mol. Biol., 2007, 2, 77-88.
35. Chang, S. The telomere protein tankyrase 1 regulates DNA damage responses at telomeres. Aging, 2010, 2, 639-642.
36. Bonicalzi, M.E.; Haince, J.F.; Droit, A.; Poirier, G.G. Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? Cell. Mol. Life Sci., 2005, 62, 739-750.
37. Min, W.; Cortes, U.; Herceg, Z; Tong, W.M.; Wang, Z.Q. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis. 2010, 31, 2058-2065.
38. Mortusewicz, O; Fouquerel, E; Amé, J.C.; Leonhardt, H.; Schreiber, V. PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms. Nucl. Acids Res., 2011, 39, 5045-5056.
39. Miwa, M.; Sugimura, T. Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-robose) by a calf thymus extract. J. Biol. Chem., 1971, 246, 6362-6364.
40. Koh, D.W.; Dawson, V.L.; Dawson, T.M. The road to survival goes through PARG. Cell Cycle, 2005, 4, 397-399.
41. Slade, D.; Dunstan, M.S.; Barkauskaite, E.; Weston, R.; Lafite, P.; Dixon, N.; Ahel, M.; Leys, D.; Ahel, I. The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature, 2011, 4; 477, 616-620.
42. Gagné, J.P.; Hendzel, M.J.; Droit, A.; Poirier, G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr. Opin. Cell Biol., 2006, 18, 145-151.
43. Botta, D.; Jacobson, M.K. Identification of a regulatory segment of Poly(ADP-ribose) Glycohydrolase. Biochemistry, 2010, 49, 7674-7682.
44. Niere, M.; Kernstock, S.; Koch-Nolte, F.; Ziegler, M. Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Mol. Cell Biol., 2008, 28, 814-824.
45. Scovassi, A.I. Mitochondrial poly(ADP-ribosylation): from old data to new perspectives. FASEB J., 2004, 18, 1487-1488.
46. Rossi, M.N.; Carbone, M.; Mostocotto, C.; Mancone, C.; Tripodi, M.; Maione, R.; Amati, P. Mitochondrial localization of PARP-1 requires interaction with mitofilin and is involved in the maintenance of mitochondrial DNA integrity. J. Biol. Chem., 2009, 284, 31616-31624.
47. Meyer, R.G.; Meyer-Ficca, M.L.; Whatcott, C.J.; Jacobson, E.L.; Jacobson, M.K. Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity. Exp. Cell Res., 2007, 313, 2920-36.
48. Niere, M.; Kernstock, S.; Koch-Nolte, F.; Ziegler, M. Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Mol. Cell Biol., 2008, 28, 814-824.
49. Whatcott, C.J.; Meyer-Ficca, M.L.; Meyer, R.G.; Jacobson, M.K. A specific isoform of poly(ADP-ribose) glycohydrolase is targeted to the mitochondrial matrix by a N-terminal mitochondrial targeting sequence. Exp. Cell Res., 2009, 315, 3477-3485.
50. Clark, J.B.; Ferris, G.M.; Pinder, S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochim. Biophys. Acta, 1971, 238, 82-85.
51. Clark, J.B.; Pinder, S. Control of the steady-state concentrations of the nicotinamide nucleotides in rat liver. Biochem. J., 1969, 114, 321-330.
52. Colyer, R.A.; Burdette, K.E.; Kidwell, W.R. Poly ADP-ribose synthesis and DNA replication in synchronized mouse L-cells. Biochem. Biophys. Res. Commun., 1973, 53, 960-966.
53. Purnell, M.R.; Whish, W.J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J., 1980, 185, 775-777.
54. Shall, S. Proceedings: Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. Biochem. J., 1975, 77, 2.
55. Durkacz, B.W.; Omidiji, O.; Gray, D.A.; Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature, 1980, 283, 593-596.
56. Shall, S.; de Murcia, G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res., 2000, 460, 1-15.
57. Dantzer, F.; Schreiber, V.; Niedergang, C.; Trucco, C.; Flatter, E.; De La Rubia, G.; Oliver, J.; Rolli, V.; Ménissier-de Murcia, J.; de Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 1999, 81: 69-75.
58. Lavrik, O.I.; Prasad, R.; Sobol, R.W.; Horton, J.K.; Ackerman, E.J.; Wilson, S.H. Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate. Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair. J. Biol. Chem., 2001, 276, 25541-25548.
59. Jagtap, P.; Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov., 2005, 4, 421-440.
60. Sestili, P.; Spadoni, G.; Balsamini, C.; Scovassi, I.; Cattabeni, F.; Duranti, E.; Cantoni, O.; Higgins, D.; Thomson, C. Structural requirements for inhibitors of poly(ADP-ribose) polymerase. J. Cancer Res. Clin. Oncol., 1990, 116, 615-622.
61. Ruf, A.; Ménissier de Murcia, J.; de Murcia, G.; Schulz, G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA, 1996, 93, 7481-7485.
62. Ruf, A.; de Murcia, G.; Schulz, G.E. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry, 1998, 37, 3893-3900.
63. Oliver, A.W.; Amé, J.C.; Roe, S.M.; Good, V.; de Murcia, G.; Pearl, L.H. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucl. Acids Res., 2004, 32, 456-464.
64. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADPribosyl) transferase. J. Biol. Chem., 1992, 267, 1569-1575.
65. Wayman, N.; McDonald, M.C.; Thompson, A.S.; Threadgill, M.D.; Thiemermann, C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur. J. Pharmacol., 2001, 430, 93-100.
66. Zingarelli, B.; O'Connor, M.; Hake, P.W. Inhibitors of poly (ADPribose) polymerase modulate signal transduction pathways in colitis. Eur. J. Pharmacol., 2003, 469, 183-194.
67. Skalitzky, D.J.; Marakovits, J.T.; Maegley, K.A.; Ekker, A.; Yu, X.H.; Hostomsky, Z.; Webber, S.E.; Eastman, B.W.; Almassy, R.; Li, J.; Curtin, N.J.; Newell, D.R.; Calvert, A.H.; Griffin, R.J.; Golding, B.T. Tricyclic benzimidazoles as potent poly(ADPribose) polymerase-1 inhibitors. J. Med. Chem., 2003, 46, 210-213.
68. Tikhe, J.G.; Webber, S.E.; Hostomsky, Z.; Maegley, K.A.; Ekkers, A.; Li, J.; Yu, X.H.; Almassy, R.J.; Kumpf, R.A.; Boritzki, T.J.; Zhang, C.; Calabrese, C.R.; Curtin, N.J.; Kyle, S.; Thomas, H.D.; Wang, L.Z.; Calvert, A.H.; Golding, B.T.; Griffin, R.J.; Newell, D.R. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADPribose) polymerase. J. Med. Chem., 2004, 47, 5467-5481.
69. Ferraris, D.; Ficco, R.P.; Pahutski, T.; Lautar, S.; Huang, S.; Zhang, J.; Kalish, V. Design and synthesis of poly(ADPribose) polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones. Bioorg. Med. Chem. Lett., 2003, 13, 2513-2518.
70. Kinoshita, T.; Nakanishi, I.; Warizaya, M.; Iwashita, A.; Kido, Y.; Hattori, K.; Fujii, T. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett., 2004, 556, 43-46.
71. Hattori, K.; Kido, Y.; Yamamoto, H.; Ishida, J.; Kamijo, K.; Murano, K.; Ohkubo, M.; Kinoshita, T.; Iwashita, A.; Mihara, K.; Yamazaki, S.; Matsuoka, N.; Teramura, Y.; Miyake, H. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J. Med. Chem., 2004, 47, 4151-4154.
72. Ishida, J.; Yamamoto, H.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; Ohkubo, M.; Kinoshita, T.; Warizaya, M.; Iwashita, A.; Mihara, K.; Matsuoka, N.; Hattori, K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg. Med. Chem., 2006, 14, 1378-1390.
73. Jagtap, P.; Soriano, F.G.; Virag, L.; Liaudet, L.; Mabley, J.; Szabo, E.; Hasko, G.; Marton, A.; Lorigados, C.B.; Gallyas, F., Jr.; Sumegi, B.; Hoyt, D.G.; Baloglu, E.; VanDuzer, J.; Salzman, A.L.; Southan, G.J.; Szabo, C. Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit. Care Med., 2002, 30, 1071-1082.
74. Jagtap, P.G.; Baloglu, E.; Southan, G.J.; Mabley, J.G.; Li, H.; Zhou, J.; van Duzer, J.; Salzman, A.L.; Szabo, C. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J. Med. Chem., 2005, 48, 5100-5103.
75. Tao, M.; Park, C.H.; Bihovsky, R.; Wells, G.J.; Husten, J.; Ator, M.A.; Hudkins, R.L. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 938-942.
76. Dunn, D.; Husten, J.; Ator, M.A.; Chatterjee, S. Novel poly(ADPribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 542-545.
77. Haince, J.F.; Rouleau, M.; Hendzel, M.J.; Masson, J.Y.; Poirier, G.G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med., 2005, 11, 456-463.
78. Sheridan, C. Genentech raises stakes on PARP inhibitors. Nat. Biotechnol., 2006, 24, 1179-1180.
79. Annunziata, C.M.; O'Shaughnessy, J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res., 2010, 16, 4517-4526.
80. Guha, M. PARP inhibitors stumble in breast cancer. Nat. Biotecnol., 2011, 29, 373-374.
81. Comen, E.A.; Robson, M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J., 2010, 16, 48-52.
82. Giansanti, V.; Donà, F.; Tillhon, M.; Scovassi, A.I. PARP inhibitors: New tools to protect from inflammation. Biochem. Pharmacol., 2010, 80, 1869-1877.
83. Mangerich, A.; Bürkle, A. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int. J. Cancer, 2011, 128, 251-265.
84. Cuzzocrea, S. Shock, inflammation and PARP. Pharmacol. Res., 2005, 52, 72-82.
85. Virag, L.; Szabo, C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J., 2001, 15, 99-107.
86. Genovese, T.; Mazzon, E.; Muia, C.; Patel, N.S.; Threadgill, M.D.; Bramanti, P.; De Sarro, A.; Thiemermann, C.; Cuzzocrea, S. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther., 2005, 312, 449-457.
87. Beneke, S.; Diefenbach, J.; Bürkle, A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int. J. Cancer, 2004, 111, 813-818.
88. Chiarugi, A. Poly(ADP-ribosyl)ation and stroke. Pharmacol. Res., 2005, 52, 15-24.
89. Graziani, G.; Szabo, C. Clinical perspectives of PARP inhibitors. Pharmacol. Res., 2005, 52, 109-118.
90. Ilnytska, O.; Lyzogubov, V.V.; Stevens, M.J.; Drel, V.R.; Mashtalir, N.; Pacher, P.; Yorek, M.A.; Obrosova, I.G. Poly(ADPribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes, 2006, 55, 1686-1694.
91. Kauppinen, T.M.; Swanson, R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience, 2007, 145, 1267-1272.
92. Pacher, P.; Szabo, C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev., 2007, 25, 235-260.
93. Szabo, C. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol. Res., 2005, 52, 34-43.
94. Virag, L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol. Res., 2005, 52, 83-92.
95. Genovese, T.; Cuzzocrea, S. Role of free radicals and poly(ADPribose) polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr. Med. Chem., 2008, 15, 477-487.
96. Sodhi, R.K.; Singh, N.; Jaggi, A.S. Poly(ADP-ribose) polymerase- 1 (PARP-1) and its therapeutic implications. Vascul. Pharmacol., 2010, 53, 77-87.
97. Underhill, C.; Toulmonde, M.; Bonnefoi, H. A review of PARP inhibitors: from bench to bedside. Annals Oncol., 2011, 22, 268-279.
98. Lupachyk, S.; Shevalye, H.; Maksimchyk, Y.; Drel, V.R.; Obrosova, I.G. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function. Free Rad. Biol. Med., 2011, 50, 1400-1409.
99. Sharma, S.S.; Kumar, A.; Kaundal, R.K. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci., 2008, 82, 570-576.
100. Negi, G.; Kumar, A.; Sharma, S.S. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun., 2010, 391, 102-106.
101. Obrosova, I.G.; Xu, W.; Lyzogubov, V.V.; Ilnytska, O.; Mashtalir, N.; Vareniuk, I.; Pavlov, I.A.; Zhang, J.; Slusher, B.; Drel, V.R. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic. Biol. Med., 2008, 44, 972-981.
102. Shevalye, H.; Maksimchyk, Y.; Watcho, P; Obrosova, I.G. Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. Biochim. Biophys. Acta, 2010, 1802, 1020-1027.
103. Chen, H.; Jia, W.; Xu, X.; Fan, Y.; Zhu, D.; Wu, H.; Xie, Z.; Zheng, Z. Upregulation of PEDF expression by PARP inhibition contributes to the decrease in hyperglycemia-induced apoptosis in HUVECs. Biochem. Biophys. Res. Commun, 2008, 369, 718-724.
104. Shrikhande, G.; Khaodhiar, L.; Scali, S.; Lima, C.; Hubbard, M.; Dudley, K.; Ganda, O.; Ferran, C.; Veves, A. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J. Vasc. Surg., 2006, 43, 760-770.
105. Koh, S.H.; Chang, D.I.; Kim, H.T.; Kim, J.; Kim, M.H.; Kim, K.S.; Bae, I.; Kim, H.; Kim, D.W.; Kim, S.H. Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology, 2005, 214, 131-139.
106. Koh, S.H.; Park, Y.; Song, C.W.; Kim, J.G.; Kim, K.; Kim, J.; Kim, M.H.; Lee, S.R.; Kim, D.W.; Yu, H.J.; Chang, D.I.; Hwang, S.J.; Kim, S.H. The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur. J. Neurosci., 2004, 20, 1461-1472.
107. Zhang, Y.; Rosenberg, P.A. Caspase-1 and poly (ADP-ribose) polymerase inhibitors may protect against peroxynitrite-induced neurotoxicity independent of their enzyme inhibitor activity. Eur. J. Neurosci., 2004, 20, 1727-1736.
108. Kamanaka, Y.; Kondo, K.; Ikeda, Y.; Kamoshima, W.; Kitajima, T.; Suzuki, Y.; Nakamura, Y.; Umemura, K. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage. Life Sci., 2004, 76, 151-162.
109. Nasrabady, S.E.; Kuzhandaivel, A.; Nistri, A. Studies of locomotor network neuroprotection by the selective poly(ADP-ribose) polymerase-1 inhibitor PJ-34 against excitotoxic injury to the rat spinal cord in vitro. Eur. J. Neurosci., 2011, 33, 2216-2227.
110. Kendirci, M.; Zsengeller, Z.; Bivalacqua, T.J.; Gur, S.; Usta, M.F.; Chen, M.; Szabo, C.; Hellstrom, W.J. Poly(Adenosine diphosphateribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J. Urol., 2005, 174, 2054-2059.
111. Nakajima, H.; Kakui, N.; Ohkuma, K.; Ishikawa, M.; Hasegawa, T. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J. Pharmacol. Exp. Ther., 2005, 312, 472-481.
112. Kaundal, R.K.; Shah, K.K.; Sharma, S.S. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci., 2006, 79, 2293-2302.
113. Goebel, D.J.; Winkler, B.S. Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J. Neurochem., 2006, 98, 1732-1745.
114. Yap, E.; Tan, W.L.; Ng, I.; Ng, Y.K. Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit? Brain Res., 2008, 1195, 130-138.
115. Lescot, T.; Fulla-Oller, L.; Palmier, B.; Po, C.; Beziaud, T.; Puybasset, L.; Plotkine, M.; Gillet, B.; Meric, P.; Marchand-Leroux, C. Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood-brain barrier permeability and edema formation after focal traumatic brain injury in rats. J. Neurotrauma, 2010, 27, 1069-1079.
116. Czapski, G.A.; Cakala, M.; Gajkowska, B.; Strosznajder, J.B. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem. Int., 2006, 49, 751-755.
117. Cavone, L.; Aldinucci, A.; Ballerini, C.; Biagioli, T.; Moroni, F.; Chiarugi, A. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult. Scler., 2011, 17, 794-807.
118. Mota, R.A.; Hernandez-Espinosa, D.; Galbis-Martinez, L.; Ordonez, A.; Minano, A.; Parrilla, P.; Vicente, V.; Corral, J.; Yelamos, J. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat strokeinduced liver injury. Crit. Care Med., 2008, 36, 526-534.
119. Kofler, J.; Otsuka, T.; Zhang, Z.; Noppens, R.; Grafe, M.R.; Koh, D.W.; Dawson, V.L.; de Murcia, J.M.; Hurn, P.D.; Traystman, R.J. Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. J. Cereb. Blood Flow Metab., 2006, 26, 135-141.
120. Diaz-Hernandez, J.I.; Moncada, S.; Bolanos, J.P.; Almeida, A. Poly(ADP-ribose) polymerase-1 protects neurons against apoptosis induced by oxidative stress. Cell Death Differ., 2007, 14, 1211-1221.
121. Alano, C.C.; Kauppinen, T.M.; Valls, A.V.; Swanson, R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. USA, 2006, 103, 9685-9690.
122. Matsuura, S.; Egi, Y.; Yuki, S.; Horikawa, T.; Satoh, H.; Akira, T. MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res., 2011, 2, 122-131.
123. Palfi, A.; Toth, A.; Hanto, K.; Deres, P.; Szabados, E.; Szereday, Z.; Kulcsar, G.; Kalai, T.; Hideg, K.; Gallyas, F., Jr.; Sumegi, B.; Toth, K.; Halmosi, R. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J. Mol. Cell. Cardiol., 2006, 41, 149-159.
124. Benko, R.; Pacher, P.; Vaslin, A.; Kollai, M.; Szabo, C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci., 2004, 75, 1255-1261.
125. Crawford, R.S.; Albadawi, H.; Atkins, M.D.; Jones, J.E.; Yoo, H.J.; Conrad, M.F., Austen, W.G. Jr, Watkins, M.T. Postischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hind-limb ischemia model. Surgery, 2010, 148, 110-118.
126. Erbel, C.; Achenbach, J.; Akhavanpoor, M.; Dengler, T.J.; Lasitschka, F.; Gleissner, C.A.; Bea, F.; Katus, H.A.; Szabo, G. PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels. Eur. J. Med. Res., 2011, 16, 367-374.
127. Szabo, G.; Soos, P.; Mandera, S.; Heger, U.; Flechtenmacher, C.; Bahrle, S.; Seres, L.; Cziraki, A.; Gries, A.; Zsengeller, Z.; Vahl, C.F.; Hagl, S.; Szabo, C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock, 2004, 21, 426-432.
128. Hauser, B.; Groger, M.; Ehrmann, U.; Albicini, M.; Bruckner, U.B.; Schelzig, H.; Venkatesh, B.; Li, H.; Szabo, C.; Speit, G.; Radermacher, P.; Kick, J. The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock, 2006, 25, 633-640.
129. Toth, O.; Szabo, C.; Kecskes, M.; Poto, L.; Nagy, A.; Losonczy, H. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci., 2006, 79, 317-323.
130. di Paola, R.; Mazzon, E.; Muia, C.; Terrana, D.; Greco, S.; Britti, D.; Santori, D.; Oteri, G.; Cordasco, G.; Cuzzocrea, S. 5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats. J. Clin. Periodontol., 2007, 34, 95-102.
131. di Paola, R.; Mazzon, E.; Xu, W.; Genovese, T.; Ferrraris, D.; Muia, C.; Crisafulli, C.; Zhang, J.; Cuzzocrea, S. Treatment with PARP-1 inhibitors, GPI-15427 or GPI-16539, ameliorates intestinal damage in rat models of colitis and shock. Eur. J. Pharmacol., 2005, 527, 163-171.
132. Mazzon, E.; Genovese, T.; Di Paola, R.; Muia, C.; Crisafulli, C.; Malleo, G.; Esposito, E.; Meli, R.; Sessa, E.; Cuzzocrea, S. Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. Eur. J. Pharmacol., 2006, 549, 149-156.
133. Zheng, J.; Devalaraja-Narashimha, K.; Singaravelu, K.; Padanilam, B.J. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am. J. Physiol. Renal Physiol., 2005, 288, 387-398.
134. Devalaraja-Narashimha, K.; Padanilam, B.J. PARP1 deficiency exacerbates diet-induced obesity in mice. J. Endocrinol. 2010, 205, 243-252.
135. Datta, R.; Naura, A.S.; Zerfaoui, M.; Errami, Y.; Oumouna, M.; Kim, H.; Ju, J.; Ronchi, V.P.; Haas, A.L.; Boulares, A.H. PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy. 2011, 66, 853-861.
136. Suzuki, Y.; Masini, E.; Mazzocca, C.; Cuzzocrea, S.; Ciampa, A.; Suzuki, H.; Bani, D. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J. Pharmacol. Exp. Ther., 2004, 311, 1241-1248.
137. Miwa, M.; Masutani, M. PolyADP-ribosylation and cancer. Cancer Sci., 2007, 98, 1528-1535.
138. Pan, Q.C.; Guo, H.Y. The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide. J. Antibiot., 1989, 42, 1860-1868.
139. Petrou, C.; Mourelatos, D.; Mioglou, E.; Dozi-Vassiliades, J.; Catsoulacos, P. Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity, and NAD levels in human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. Teratog. Carcinog. Mutagen., 1990, 10, 321-331.
140. Jacob, D.A.; Bahra, M.; Langrehr, J.M.; Boas-Knoop, S.; Stefaniak, R.; Davis, J.; Schumacher, G.; Lippert, S.; Neumann, U.P. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J. Gastroenterol. Hepatol., 2007, 22, 738-748.
141. Schlicker, A.; Peschke, P.; Bürkle, A.; Hahn, E.W.; Kim, J.H. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol., 1999, 75, 91-100.
142. Muñoz-Gámez, J.A.; Martin-Oliva, D.; Aguilar-Quesada, R.; Canuelo, A.; Nunez, M.I.; Valenzuela, M.T.; Ruiz de Almodovar, J.M.; de Murcia, G.; Oliver, F.J. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem. J., 2005, 386, 119-125.
143. Calabrese, C.R.; Almassy, R.; Barton, S.; Batey, M.A.; Calvert, A.H.; Canan-Koch, S.; Durkacz, B.W.; Hostomsky, Z.; Kumpf, R.A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D.R.; Notarianni, E.; Stratford, I.J.; Skalitzky, D.; Thomas, H.D.; Wang, L.Z.; Webber, S.E.; Williams, K.J.; Curtin, N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst., 2004, 96, 56-67.
144. Brock, W.A.; Milas, L.; Bergh, S.; Lo, R.; Szabo, C.; Mason, K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett., 2004, 205, 155-160.
145. Mason, K.A.; Valdecanas, D.; Hunter, N.R.; Milas, L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest. New Drugs, 2008, 26, 1-5.
146. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Mazzon, E.; Vergati, M.; Forini, O.; Lapidus, R.; Xu, W.; Dorio, A.S.; Zhang, J.; Cuzzocrea, S.; Graziani, G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J., 2006, 20, 1709-1711.
147. Domagala, P.; Lubinski, J.; Domagala, W. Iniparib in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011, 364, 1780.
148. O'Shaughnessy, J.; Osborne, C.; Pippen, J.E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I.C.; Sherman, B.M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011, 364, 205-214.
149. Carden, C.P.; Yap, T.A.; Kaye, S.B. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr. Opin. Oncol., 2010, 22, 473-480.
150. Narod, S.A. BRCA mutations in the management of breast cancer: the state of the art. Nat. Rev. Clin. Oncol., 2010, 7, 702-707.
151. Albert, J.M.; Cao, C.; Kim, K.W.; Willey, C.D.; Geng, L.; Xiao, D.; Wang, H.; Sandler, A.; Johnson, D.H.; Colevas, A.D.; Low, J.; Rothenberg, M.L.; Lu, B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res., 2007, 13, 3033-3042.
152. Donawho, C.K.; Luo, Y.; Luo, Y.; Penning, T.D.; Bauch, J.L.; Bouska, J.J.; Bontcheva-Diaz, V.D.; Cox, B.F.; DeWeese, T.L.; Dillehay, L.E.; Ferguson, D.C.; Ghoreishi-Haack, N.S.; Grimm, D.R.; Guan, R.; Han, E.K.; Holley-Shanks, R.R.; Hristov, B.; Idler, K.B.; Jarvis, K.; Johnson, E.F.; Kleinberg, L.R.; Klinghofer, V.; Lasko, L.M.; Liu, X.; Marsh, K.C.; McGonigal, T.P.; Meulbroek, J.A.; Olson, A.M.; Palma, J.P.; Rodriguez, L.E.; Shi, Y.; Stavropoulos, J.A.; Tsurutani, A.C.; Zhu, G.D.; Rosenberg, S.H.; Giranda, V.L.; Frost, D.J. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13, 2728-2737.
153. Patel, A.G.; Flatten, K.S.; Schneider, P.A.; Dai, N.T.; McDonald, J.S.; Poirier, G.G.; Kaufmann, S.H. Enhanced killing of cancer cells by Poly(ADP-ribose) Polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J. Biol. Chem., 2011, 1, 1-17
154. D'Onofrio, G.; Tramontano, F.; Dorio, A.S.; Muzi, A.; Maselli, V.; Fulgione, D.; Graziani, G.; Malanga, M.; Quesada, P. Poly(ADPribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochem. Pharmacol., 2011, 81, 194-202.
155. Castiel, A.; Visochek, L.; Mittelman, L.; Dantzer, F.; Izraeli, S.; Cohen-Armon, M. A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer, 2011, 11, 412.
156. Mendes, F.; Groessl, M.; Nazarov, A.A.; Tsybin, Y.O.; Sava, G.; Santos, I.; Dyson, P.J.; Casini, A. Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J. Med. Chem., 2011, 54, 2196-2206.
157. Cipak, L.; Jantova, S. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. Neoplasma. 2010, 57, 401-405.
158. Drew, Y.; Plummer, R. The emerging potential of poly(ADPribose) polymerase inhibitors in the treatment of breast cancer. Curr. Opin. Obstet. Gynecol., 2010, 22, 67-71.
159. Chiarugi, A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol. Sci., 2011, 1-7.
160. Javle, M.; Curtin, N.J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer, 2011, 105, 1114-1122.
161. Wesierska-Gadek, J.; Składanowski, A. Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. Future Med. Chem., 2012, 4, 51-72.
162. Ellisen, L.W. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell, 2011, 19, 165-167.
163. Kelley, M.R. DNA repair inhibitors: where do we go from here?. DNA Repair, 2011, 10, 1183-1185.
164. Telli, M.L. PARP inhibitors in cancer: moving beyond BRCA. Lancet Oncol., 2011, 9, 827-828.
165. Wang, X.; Weaver, D.T. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am. J. Cancer Res., 2011, 1, 301-327.
166. Villanueva, T. Expanding the horizons of PARP inhibitors. Nat. Rev. Cancer, 2010, 10, 814.
167. Plummer, R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?. Breast Cancer Res., 2011, 13, 218.
168. Shall, S.; Gaymes, T.; Farzaneh, F.; Curtin, N.; Mufti, G.J. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. Methods Mol. Biol., 2011, 780, 239-266.
169. Tulin, A. Re-evaluating PARP1 inhibitor in cancer. Nat. Biotechnol., 2011, 29, 1078-1079.
170. Blackburn, E.H.; Greider, C.W.; Szostak, J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med., 2006, 12, 1133-1138.
171. Harley, C.B.; Futcher, A.B.; Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature, 1990, 345, 458-460.
172. Hiyama, E.; Hiyama, K. Telomerase as tumor marker. Cancer Lett., 2003, 194, 221-233.
173. Folini, M.; Venturini, L.; Cimino-Reale, G.; Zaffaroni, N. Telomeres as targets for anticancer therapies. Expert Opin. Ther. Targets, 2011, 15, 579-593.
174. Ouellette, M.M.; Wright, W.E.; Shay, J.W. Targeting telomeraseexpressing cancer cells. J. Cell. Mol. Med., 2011, 15, 1433-1442.
175. Nugent, C.I.; Lundblad, V. The telomerase reverse transcriptase: components and regulation. Genes Dev., 1998, 12, 1073-1085.
176. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 2005, 19, 2100-2110.
177. Martínez, P.; Blasco, M.A. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer, 2011, 11, 161-176.
178. Pinto, A.R.; Li, H.; Nicholls, C.; Liu, J.P. Telomere protein complexes and interactions with telomerase in telomere maintenance. Front. Biosci., 2011, 16, 187-207.
179. Hsiao, S.J.; Smith, S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie, 2008, 90, 83-92.
180. Seimiya, H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br. J. Cancer, 2006, 94, 341-345.
181. Zhang, H.; Yang, M.H.; Zhao, J.J.; Chen, L.; Yu, S.T.; Tang, X.D.; Fang, D.C.; Yang, S.M. Inhibition of tankyrase 1 in human gastric cancer cells enhances telomere shortening by telomerase inhibitors. Oncol. Rep., 2010, 24, 1059-1065.
182. Narwal, M.; Venkannagari, H.; Lehtiö, L. Structural basis of selective inhibition of human Tankyrases. J. Med. Chem., 2012, DOI:10.1021/jm201510p.
183. Isabelle, M.; Moreel, X.; Gagné, J.P.; Rouleau, M.; Ethier, C.; Gagné, P.; Hendzel, M.J.; Poirier, G.G. Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry. Proteome Sci., 2010, 13, 22.
184. Troiani, S.; Lupi, R.; Perego, R.; Depaolini, S.R.; Thieffine, S.; Bosotti, R.; Rusconi, L. Identification of candidate substrates for poly(ADP-ribose) polymerase-2 (PARP2) in the absence of DNA damage using high-density protein microarrays. FEBS J., 2011, 278, 3676-3687.
185. Sunderland, P.T.; Woon, E.C.; Dhami, A.; Bergin, A.B.; Mahon, M.F.; Wood, P.J.; Jones, L.A.; Tully, S.R.; Lloyd, M.D.; Thompson, A.S.; Javaid, H.; Martin, N.M.; Threadgill, M.D. 5-Benzamidoisoquinolin-1-ones and 5-(?-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). J. Med. Chem., 2011, 54, 2049-2059.
186. Meyer, R.G.; Meyer-Ficca, M.L.; Jacobson, E.L.; Jacobson, M.K. Human poly(ADP-ribose) glycohydrolase (PARG) gene and the common promoter sequence it shares with inner mitochondrial membrane translocase 23 (TIM23). Gene, 2003, 314, 181-190.
187. Meyer-Ficca, M.L.; Meyer, R.G.; Coyle, D.L.; Jacobson, E.L.; Jacobson, M.K. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp. Cell Res., 2004, 297, 521-532.
188. Oka, S.; Kato, J.; Moss, J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem., 2006, 281, 705-713.
189. Koh, D.W.; Lawler, A.M.; Poitras, M.F.; Sasaki, M.; Wattler, S.; Nehls, M.C.; Stoger, T.; Poirier, G.G.; Dawson, V.L.; Dawson, T.M. Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc. Natl. Acad. Sci. USA, 2004, 101, 17699-17704.
190. Cortes, U.; Tong, W.M.; Coyle, D.L.; Meyer-Ficca, M.L.; Meyer, R.G.; Petrilli, V.; Herceg, Z.; Jacobson, E.L.; Jacobson, M.K.; Wang, Z.Q. Depletion of the 110-kilodalton isoform of poly(ADPribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. Mol. Cell Biol., 2004, 24, 7163-7178.
191. Hanai, S.; Kanai, M.; Ohashi, S.; Okamoto, K.; Yamada, M.; Takahashi, H.; Miwa, M. Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA, 2004, 101, 82-86.
192. Slama, J.T.; Aboul-Ela, N.; Jacobson, M.K. Mechanism of inhibition of poly(ADP-ribose) glycohydrolase by adenosine diphosphate (hydroxymethyl)pyrrolidinediol. J. Med. Chem., 1995, 38, 4332-4336.
193. Koh, D.W.; Patel, C.N.; Ramsinghani, S.; Slama, J.T.; Oliveira, M.A.; Jacobson, M.K. Identification of an inhibitor binding site of poly(ADP-ribose) glycohydrolase. Biochemistry, 2003, 42, 4855-4863.
194. Tsai, Y.J.; Aoki, T.; Maruta, H.; Abe, H.; Sakagami, H.; Hatano, T.; Okuda, T.; Tanuma, S. Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly(ADP-ribose) glycohydrolase. J. Biol. Chem., 1992, 267, 14436-14442.
195. Falsig, J.; Christiansen, S.H.; Feuerhahn, S.; Burkle, A.; Oei, S.L.; Keil, C.; Leist, M. Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention: assessment of currently available pharmacological tools. Eur. J. Pharmacol., 2004, 497, 7-16.
196. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Vergati, M.; Forini, O.; Lacal, P.M.; Ruffini, F.; Gold, B.; Li, W.; Zhang, J.; Graziani, G. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur. J. Cancer, 2005, 41, 2948-2957.
197. Okita, N.; Ashizawa, D.; Ohta, R.; Abe, H.; Tanuma, S. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADPribose). Biochem. Biophys. Res. Commun., 2010, 392, 485-489.
198. Steffen, J.D.; Coyle, D.L.; Damodaran, K.; Beroza, P.; Jacobson, M.K. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). J. Med. Chem., 2011, 54, 5403-5413.
199. Cuzzocrea, S.; Mazzon, E.; Genovese, T.; Crisafulli, C.; Min, W.K.; Di Paola, R.; Muia, C.; Li, J.H.; Malleo, G.; Xu, W.; Massuda, E.; Esposito, E.; Zhang, J.; Wang, Z.Q. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. Free Radic. Biol. Med., 2007, 42, 90-105.
200. Finch, K.E.; Knezevic, C.E.; Nottbohm, A.C.; Partlow, K.C.; Hergenrother, P.J. Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG). ACS Chem. Biol., 2012, DOI:10.1021/cb200506t.
201. Khan, J.A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol., 2006, 13, 582-588.
202. Takahashi, R.; Nakamura, S.; Nakazawa, T.; Minoura, K.; Yoshida, T.; Nishi, Y.; Kobayashi, Y.; Ohkubo, T. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J. Biochem., 2010, 147, 95-107.
203. Hufton, S.E.; Moerkerk, P.T.; Brandwijk, R.; de Bruine, A.P.; Arends, J.W.; Hoogenboom, H.R. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett., 1999, 463, 77-82.
204. van Beijnum, J.R.; Moerkerk, P.T.; Gerbers, A.J.; De Bruine, A.P.; Arends, J.W.; Hoogenboom, H.R.; Hufton, S.E. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. J. Cancer, 2002, 101, 118-127.
205. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res., 2003, 63, 7436-7442.
206. Muruganandham, M.; Alfieri, A.A.; Matei, C.; Chen, Y.; Sukenick, G.; Schemainda, I.; Hasmann, M.; Saltz, L.B.; Koutcher, J.A. Metabolic signatures associated with a NAD synthesis inhibitorinduced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin. Cancer Res., 2005, 11, 3503-3513.
207. Wosikowski, K.; Mattern, K.; Schemainda, I.; Hasmann, M.; Rattel, B.; Loser, R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res., 2002, 62, 1057-1062.
208. Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C.R.; Sorba, G.; Canonico, P.L.; Genazzani, A.A.; Tron, G.C.; Billington, R.A. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. Chem. Med. Chem., 2008, 3, 771-779.
209. Pittelli, M.; Formentini, L.; Faraco, G.; Lapucci, A.; Rapizzi, E.; Cialdai, F.; Romano, G.; Moneti, G.; Moroni, F.; Chiarugi, A. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J. Biol. Chem., 2010, 285, 34106-34114.
210. Chandra, N.; Bhagavat, R.; Sharma, E.; Sreekanthreddy, P.; Somasundaram, K. Virtual screening, identification and experimental testing of novel inhibitors of PBEF1/Visfatin/NMPRTase for glioma therapy. J. Clin. Bioinform., 2011, 1, 1-12.
211. Soldani, C.; Scovassi, A.I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update. Apoptosis, 2002, 7, 321-328.
212. Scovassi, A.I. The poly(ADP-ribosylation) story: a long route from Cinderella to Princess. Riv. Biol., 2007, 100, 351-360.
213. Abd Elmageed, Z.Y.; Naura, A.S.; Errami, Y.; Zerfaoui, M. The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal., 2012, 24, 1-8.